相关实验视频
Updated: Sep 14, 2025
07:23
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
6.2K
基于纳米体的Pannexin1通道抑制剂增加了心脏缺血/再输血后的存活率
Olga M Rusiecka1,2, Filippo Molica3,4, Linda Clochard1,2
1Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Cell and tissue research
|July 22, 2025
概括
针对Pannexin1 (PANX1) 通道的新纳米体显示出治疗心脏缺血/再输液损伤的前景. 通过抑制ATP释放和减少白细胞粘附,Nanobody-1提高了小鼠的生存率.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 纳米医学是一种纳米医学.
背景情况:
- 心脏缺血/反 (I/R) 损伤仍然是一个临床挑战,尽管反疗法.
- 泛素1 (PANX1) 通道通过ATP释放调解白细胞向受伤的心脏的招募.
- 现有的PANX1抑制剂缺乏特异性和体内稳定性,需要新的治疗方法.
研究的目的:
- 为了验证针对心血管应用的PANX1通道的纳米体.
- 在心脏I/R损伤的临床前模型中评估特定的PANX1抑制纳米体的疗效.
主要方法:
- 在实验室中验证纳米体特异性和PANX1通道抑制.
- 对中性粒细胞对内皮细胞粘附的纳米体影响的评估.
- 在小鼠心脏I/R损伤模型中对纳米体性能的ex vivo和in vivo评估.
主要成果:
- 两个纳米体,Nb1和Nb9,减少了中性粒细胞的粘附.
- Nb1没有损害ex vivo左心室功能,而Nb9显示了心脏表现下降的趋势.
- 在体内,Nb1在再注射时的使用增加了小鼠的存活率,尽管心脏病发作大小与对照组相比保持不变.
结论:
- 纳米体-1 (Nb1) 特别抑制通过PANX1通道的内皮ATP释放.
- 在心脏I/R损伤的小鼠模型中,Nb1限制白细胞粘附,并提高存活率.
- 需要进一步的研究来阐明Nb1心脏保护作用背后的精确分子机制.
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
693
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
693
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K